HUE044737T2 - Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel - Google Patents

Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel

Info

Publication number
HUE044737T2
HUE044737T2 HUE14730660A HUE044737T2 HU E044737 T2 HUE044737 T2 HU E044737T2 HU E14730660 A HUE14730660 A HU E14730660A HU E044737 T2 HUE044737 T2 HU E044737T2
Authority
HU
Hungary
Prior art keywords
alzheimer
treatment
pooled immunoglobulin
subpopulations
disease
Prior art date
Application number
Other languages
English (en)
Inventor
David Gelmont
Julia Singer
Sandor Fritsch
Hans-Peter Schwarz
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of HUE044737T2 publication Critical patent/HUE044737T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE14730660 2013-05-06 2014-05-05 Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel HUE044737T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361855062P 2013-05-06 2013-05-06
US201361833447P 2013-06-10 2013-06-10
US201361844732P 2013-07-10 2013-07-10
US201361886464P 2013-10-03 2013-10-03

Publications (1)

Publication Number Publication Date
HUE044737T2 true HUE044737T2 (hu) 2019-11-28

Family

ID=50943566

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14730660 HUE044737T2 (hu) 2013-05-06 2014-05-05 Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel

Country Status (12)

Country Link
US (3) US20140328856A1 (hu)
EP (2) EP3552624A1 (hu)
JP (1) JP6424210B2 (hu)
AU (4) AU2014262890B2 (hu)
DK (1) DK2994160T3 (hu)
ES (1) ES2740127T3 (hu)
HR (1) HRP20191383T1 (hu)
HU (1) HUE044737T2 (hu)
LT (1) LT2994160T (hu)
PL (1) PL2994160T3 (hu)
PT (1) PT2994160T (hu)
WO (1) WO2014182631A1 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106170563A (zh) 2014-03-21 2016-11-30 爱尔真公司 用于治疗神经病症的方法
US10568568B2 (en) * 2014-08-27 2020-02-25 Capnia, Inc. Methods for immune globulin administration
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3347002B1 (en) * 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
CN114019170A (zh) * 2016-01-20 2022-02-08 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
KR20220107322A (ko) * 2016-08-18 2022-08-02 알카헤스트 인코포레이티드 노화-관련된 인지 장애 치료제로서의 혈장 분획
UA127828C2 (uk) * 2017-04-26 2024-01-17 Алкахест, Інк. Спосіб застосування фракції білків плазми крові для лікування когнітивних порушень
JOP20200041A1 (ar) 2017-08-22 2020-02-20 Biogen Ma Inc تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
FI128916B (en) * 2018-02-05 2021-03-15 Vetcare Oy Health-promoting composition and method for its preparation
KR102276545B1 (ko) * 2019-09-05 2021-07-15 고려대학교 산학협력단 Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
EP4236988A1 (en) * 2020-10-30 2023-09-06 Rush University Medical Center Intranasal immunotherapy for the treatment of alzheimer's disease
AU2023216231A1 (en) * 2022-02-03 2024-08-01 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (hu) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
WO2003028668A2 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
WO2006091332A2 (en) 2005-02-23 2006-08-31 Alza Corporation Intranasal administration of active agents to the central nervous system
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
PT1981540E (pt) * 2006-01-30 2013-05-07 Grifols Therapeutics Inc Método de tratamento e profilaxia de doenças relacionadas com a deposição de amilóides utilizando igm
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2011034604A2 (en) 2009-09-17 2011-03-24 Baxter Healthcare, S.A. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
JP2013509985A (ja) * 2010-04-13 2013-03-21 バクスター、インターナショナル、インコーポレイテッド アルツハイマー病の静脈内免疫グロブリン処置における脳室拡大速度の使用
WO2011142778A1 (en) * 2010-05-13 2011-11-17 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
CN103282042B (zh) * 2010-09-17 2014-12-10 巴克斯特国际公司 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白
KR20130139153A (ko) * 2011-01-18 2013-12-20 백스터 인터내셔널 인코포레이티드 인간 혈액 중 항-베타 아밀로이드 항체의 측정
US20120251524A1 (en) * 2011-04-01 2012-10-04 Baxter Healthcare S.A. Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
CN104010656B (zh) * 2011-09-24 2016-02-24 德国杰特贝林生物制品有限公司 使用免疫球蛋白和c1-抑制剂的联合疗法

Also Published As

Publication number Publication date
DK2994160T3 (da) 2019-08-12
AU2020257034A1 (en) 2020-11-12
US20140328856A1 (en) 2014-11-06
US20210238267A1 (en) 2021-08-05
AU2014262890B2 (en) 2019-01-31
HRP20191383T1 (hr) 2020-02-07
EP2994160B1 (en) 2019-07-03
EP3552624A1 (en) 2019-10-16
PT2994160T (pt) 2019-08-07
JP6424210B2 (ja) 2018-11-14
PL2994160T3 (pl) 2019-10-31
AU2019202459B2 (en) 2020-07-23
AU2019202459A1 (en) 2019-05-02
AU2024201051A1 (en) 2024-03-14
EP2994160A1 (en) 2016-03-16
JP2016518411A (ja) 2016-06-23
WO2014182631A1 (en) 2014-11-13
ES2740127T3 (es) 2020-02-05
US20190144530A1 (en) 2019-05-16
AU2014262890A1 (en) 2015-11-26
LT2994160T (lt) 2019-08-26

Similar Documents

Publication Publication Date Title
HUE044737T2 (hu) Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
IL266648B (en) A method for treating Parkinson's disease
IL245643B (en) Install closure between mri and incubator
HK1220468A1 (zh) 的人抗體
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
HK1219653A1 (zh) 治療線粒體疾病的方法
HK1225732A1 (zh) 作為rorc調節劑用於治療自身免疫性疾病的5，6，7，8-四氫-5，8-亞甲基噌啉衍生物
ES2982165T3 (es) Tratamiento de piezas estampadas en caliente
EP2978446A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
GB201310150D0 (en) Methods and compositions relating to alzheimer's disease
EP3086846A4 (en) Diagnosing and treating alzheimer's disease
IL243637B (en) PPAR-sparing compounds for the treatment of metabolic diseases
DK2983706T3 (en) Use of Immune Suppressive Domains as Medicaments
GB201311036D0 (en) Biomarkers for alzheimer's Disease
IL241482B (en) A method for treating Parkinson's disease
GB201511453D0 (en) Treatment of alzheimer's disease
GB201310101D0 (en) Treatment of freidreich's ataxia
GB201414038D0 (en) Alzheimer's disease
GB201304393D0 (en) Time's tremor
UA26689S (uk) Ущільнювач з'єднань механізмів транспортного засобу
BR302013002169S1 (pt) "configuração aplicada em odorizador automotivo"
ES1092430Y (es) "Anafe paellero"
GB201306413D0 (en) The local treatment of ophthalmic diseases
UA25914S (uk) Шпилька для з'єднання деталей транспортного засобу
GB201321628D0 (en) Treatment of disease